MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, S.
Right arrow Articles by Fisher, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, S.
Right arrow Articles by Fisher, L. M.

Vol. 57, Issue 4, 784-791, April 2000

Mutations at Arg486 and Glu571 in Human Topoisomerase IIalpha Confer Resistance to Amsacrine: Relevance for Antitumor Drug Resistance in Human Cells1

Sandhiya Patel, Beatrice A. Keller, and L. Mark Fisher

Molecular Genetics Group, Department of Biochemistry, St. George's Hospital Medical School, University of London, London, United Kingdom

Human topoisomerase II, a nuclear protein involved in chromosome segregation, is the target of amsacrine and other clinically important anticancer drugs. The enzyme is expressed as alpha  and beta  isoforms whose mutation/down-regulation has been implicated in drug resistance. To understand the role of target mutations in cellular drug resistance, we have used yeast to select and characterize plasmid-borne human topoisomerase IIalpha mutants resistant to amsacrine. Single point changes of Glu571 to Lys (E571K) or Arg486 to Lys (R486K) in the conserved PLRGK motif, both of which reside in the GyrB homology domain of human topoisomerase IIalpha , were frequently selected and could be shown in vivo to confer >25-fold and >100-fold resistance, respectively, to amsacrine and ~3-fold cross-resistance to etoposide. Highly purified E571K and R486K human topoisomerase IIalpha proteins required 100-fold higher levels of amsacrine to induce DNA cleavage similar to that of wild-type protein, consistent with a resistance mechanism involving reduced cleavable complex formation. Our functional studies of the R486K mutation, previously identified in two amsacrine-resistant human cell lines and in human biopsy material, establish unequivocally that it confers resistance, and suggest mechanisms for its phenotypic expression in vivo. These results differ significantly from previous work using yeast topoisomerase II as a model system: introduction of the equivalent mutation to R486K (R476K) into the yeast enzyme did not give amsacrine resistance. We conclude that species-specific differences in topoisomerase II enzymes can affect the drug resistance phenotype of particular mutations and highlight the need to study the relevant human homolog.


1 Part of this work was presented in abstract form at the Ninth Conference on DNA Topoisomerases in Therapy, New York, NY, October, 1998.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
C. Leontiou, G. P. Watters, K. L. Gilroy, P. Heslop, I. G. Cowell, K. Craig, R. N. Lightowlers, J. H. Lakey, and C. A. Austin
Differential Selection of Acridine Resistance Mutations in Human DNA Topoisomerase IIbeta Is Dependent on the Acridine Structure
Mol. Pharmacol., April 1, 2007; 71(4): 1006 - 1014.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
K. L. Gilroy, C. Leontiou, K. Padget, J. H. Lakey, and C. A. Austin
mAMSA resistant human topoisomerase II{beta} mutation G465D has reduced ATP hydrolysis activity
Nucleic Acids Res., March 20, 2006; 34(5): 1597 - 1607.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Leontiou, J. H. Lakey, R. Lightowlers, R. M. Turnbull, and C. A. Austin
Mutation P732L in Human DNA Topoisomerase IIbeta Abolishes DNA Cleavage in the Presence of Calcium and Confers Drug Resistance
Mol. Pharmacol., January 1, 2006; 69(1): 130 - 139.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Leontiou, J. H. Lakey, and C. A. Austin
Mutation E522K in Human DNA Topoisomerase II{beta} Confers Resistance to Methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and Methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but Hypersensitivity to Etoposide
Mol. Pharmacol., September 1, 2004; 66(3): 430 - 439.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics